Greater use of Benlysta, Saphnelo seen in US, EU to treat lupus

In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for autoimmune diseases is tied to serious side effects — among people with moderate to severe lupus. To that end, healthcare professionals are increasingly prescribing biological therapies like Benlysta…

Lupus Clinical Trials May Not Be Representative of Real-World Population, Report Suggests

Patients participating in Phase 3 clinical trials testing new therapies for systemic lupus erythematosus (SLE) are not necessarily representative of real-world patient populations, according to a new report. Even if the therapies being investigated reach the market, real-world experiences may differ significantly from trial results because many lupus patients…